Market closed · Next open: Monday 9:30 AM ET
Last update: Aug 28, 2026, 6:10 PM ET
Bio-Rad Laboratories, Inc.
$387.70 0.57% today
Market Closed

Why Bio-Rad Laboratories, Inc. (BIO) stock moved

Updated Aug 30, 2026

Bio-Rad Laboratories, Inc. (BIO) shares fell 0.6% to $387.70 as of August 30, 2026, a slight decline from the prior close of $389.94. BestStocks flagged the session as a major change for BIO. The move is tied to price move up. Below, we break down what changed for BIO, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

BIO fell 0.6% to $387.70

BIO fell 0.6% in its latest session, moving from $389.94 to $387.70.

Material / EarningsWeak confidence
Rel. volume
0.6×
Below Avg
Vs peers
No comparable peers
Market cap
$10.4B
New York Stock Exchange
Analyst target
$350
-9.7% vs price
Price chart
Not enough price data.
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Bio-Rad Laboratories, Inc. investors

For Bio-Rad Laboratories, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Bio-Rad Laboratories, Inc. (BIO) moved +0.98% from $351.10 to $354.54 on 2026-08-10; Bio-Rad Laboratories, Inc. (BIO) moved +3.92% from $339.18 to $352.47 on 2026-08-07, reaching a new 30-day high. Weighing against that: Material negative event; Negative session, down 0.6%. Wall Street's consensus price target sits at $350.00, implying -9.7% downside from $387.70. BestStocks rates the overall signal quality weak (33/100). With earnings roughly 60 days out, the next report is the most likely near-term test of the move.

BIO price reaction

BIO last traded at $387.70, down $2.24 (-0.57%) from the previous close of $389.94. The session traded on 0.6× average volume (below avg), so participation was unremarkable.

Bullish and bearish analyst opinions on Bio-Rad Laboratories, Inc. (BIO)

The consensus analyst price target on Bio-Rad Laboratories, Inc. (BIO) is $350.00, 9.7% below the recent $387.70. Over the past 90 days analysts logged 0 upgrades, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on BIO line up.

The bullish case

  • The Street's most bullish target is $390.00 (+0.6%).
  • Bio-Rad Laboratories, Inc. (BIO) moved +0.98% from $351.10 to $354.54 on 2026-08-10.

The bearish case

  • The consensus analyst price target of $350.00 sits 9.7% below the recent $387.70, so the average target sees limited room to run.
  • The most bearish analyst target is $310.00 (-20.0%).
  • Material negative event.
  • Negative session, down 0.6%.
  • BIO moved -2.95% from $292.50 to $283.86 on 2026-07-08.
Bull vs bear balanceBearish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Aug 30, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $350-9.7%
= 4 maintains
RBC Capital maintained Outperform · 2026-08-07
SEC filings watch
No recent filings
Peer context
BIO-0.6%

Previous notable changes for BIO

Material / Earnings2026-08-25
Bio-Rad Laboratories, Inc. (BIO) moved +1.65% from $384.00 to $390.34 on 2026-08-25. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move appears to be technical, with the stock reaching a new 30-day high.
Material / Earnings2026-08-24
Bio-Rad Laboratories, Inc. (BIO) moved -0.61% from $384.09 to $381.76 on 2026-08-24. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move occurred as BIO reached a new 30-day high, suggesting technical positioning.
Material / Earnings2026-08-21
Bio-Rad Laboratories, Inc. (BIO) moved -1.50% from $385.80 to $380.03 on 2026-08-21. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.4x the 5-day average, and the stock reached a new 30-day high, suggesting modest technical activity rather than a driven event.
Material / Earnings2026-08-19
Bio-Rad Laboratories, Inc. (BIO) moved +3.27% from $352.71 to $364.26 on 2026-08-19, reaching a new 30-day high. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Upcoming catalysts & outlook
Next earnings
2026-10-29 (est.)
in 60 days
Thesis shift
Bearish Shift
bearish signal
Risk level
Medium
from change events

Frequently asked questions about BIO

Why did Bio-Rad Laboratories, Inc. (BIO) stock move?

BIO fell 0.6% to $387.70. No single company-specific catalyst was confirmed during the move window, and it looks technical.

How much did BIO stock fall?

BIO lost 0.57% ($2.24) versus the prior close of $389.94, last trading at $387.70 on 0.6× average volume.

When is Bio-Rad Laboratories, Inc.'s next earnings date?

BIO's next earnings report is estimated for 2026-10-29 — about 60 days away.

What is the analyst price target for BIO?

The consensus analyst price target for BIO is $350.00, about 9.7% below the current $387.70. Over the past 90 days, analysts recorded 0 upgrades, 4 maintains, and 0 downgrades.

How BestStocks tracks BIO

This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for BIO, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 30, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataFMP earnings & estimatesSEC EDGAR filingsAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.